Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
John N. Allan, MD–has disclosed that he is a consultant for Abbvie, Genentech, Pharmacyclics, and Verastem.
Michael Wang, MD– has disclosed that he is a consultant for AstraZeneca, AxImmune, Celgene, Janssen, MoreHealth and Pulse Biosciences; receives grant/research support from Janssen; AstraZeneca, BeiGene, Celgene, Kite Pharma; Juno Therapeutics and Pharmacyclics. He is also a major stockholder in MoreHealth.

Presenters:
John N. Allan, MD–has disclosed that he is a consultant for Abbvie, Genentech, Pharmacyclics, and Verastem.
Danielle M. Brander, MD–has disclosed that she is a consultant for Abbvie, Genentech, Pharmacyclics, T6 Therapeutics, and Teva. She receives other financial/material support from the Novartis.
Nina Wagner-Johnston, MD–has disclosed that she is a consultant for ADC Therapeutics, Janssen, and Juno.
Loretta J. Nastoupil, MD–has disclosed that she is a consultant for Celgene, Genentech, Gilead, and Merck.
Stephen E. Spurgeon, MD–has disclosed that he is a consultant for Gilead and Pharmacyclics. He also receives grant/research support Acerta, AstraZeneca, Bristol-Myers Squibb, and Genentech.